Rotmensch H H, Rotmensch S, Elkayam U
Drugs. 1987 Jun;33(6):623-33. doi: 10.2165/00003495-198733060-00005.
Cardiac arrhythmia is one of the most common reasons for cardiac consultation during pregnancy. Fortunately, malignant arrhythmias during the course of normal gestation are rare, and the relatively common complaint of palpitations is usually due to benign arrhythmias. However, in pregnant patients with organic heart disease, arrhythmias are often triggered by the haemodynamic burden of pregnancy and may be the first manifestation of the disease. In addition, rhythm abnormalities in patients with limited cardiac reserves may have significant haemodynamic consequences and can compromise fetal well-being. Any woman who presents with rhythm disorders during pregnancy should undergo a diagnostic evaluation to rule out an underlying disease, including cardiac, pulmonary, endocrine, or metabolic disease. Additionally, removal of precipitating factors, such as excessive ingestion of caffeine and/or alcohol, cigarette smoking, drug abuse or therapy with arrhythmogenic compounds, is indicated (as these measures are desirable in any pregnant woman). Antiarrhythmic drug therapy is indicated in such patients only in symptomatic or haemodynamically significant arrhythmias. In cases where organic heart disease or any other cause for arrhythmia is identified, the underlying disease should be treated first. Antiarrhythmic drug therapy is indicated when arrhythmias persist or as a prophylactic measure. In principle, the approach to drug therapy in pregnant patients is similar to that in non-pregnant patients. However, special consideration should be given to drug selection in order to avoid adverse effects to the fetus. Those antiarrhythmics that have been shown to be relatively safe during pregnancy include digoxin, quinidine, procainamide, some beta-blocking drugs and lignocaine (lidocaine). In addition to careful drug selection, the smallest effective dose should be used and the indication for antiarrhythmic therapy should be periodically reassessed during the course of pregnancy.
心律失常是孕期心脏科会诊最常见的原因之一。幸运的是,正常妊娠期间恶性心律失常很少见,相对常见的心悸主诉通常是由良性心律失常引起的。然而,患有器质性心脏病的孕妇,心律失常常由妊娠的血流动力学负担诱发,且可能是该病的首发表现。此外,心脏储备功能有限的患者出现的节律异常可能会产生显著的血流动力学后果,并可能危及胎儿健康。任何在孕期出现节律紊乱的女性都应接受诊断评估,以排除潜在疾病,包括心脏、肺部、内分泌或代谢疾病。此外,应去除诱发因素,如过量摄入咖啡因和/或酒精、吸烟、药物滥用或使用致心律失常化合物进行治疗(因为这些措施对任何孕妇都是可取的)。仅当此类患者出现症状性或血流动力学显著的心律失常时,才需要进行抗心律失常药物治疗。如果确定存在器质性心脏病或任何其他心律失常原因,应首先治疗潜在疾病。当心律失常持续存在或作为预防措施时,需进行抗心律失常药物治疗。原则上,孕妇的药物治疗方法与非孕妇相似。然而,在药物选择时应特别考虑,以避免对胎儿产生不良影响。那些已被证明在孕期相对安全的抗心律失常药物包括地高辛、奎尼丁、普鲁卡因胺、一些β受体阻滞剂和利多卡因。除了谨慎选择药物外,应使用最小有效剂量,并在孕期定期重新评估抗心律失常治疗的指征。